Vitamin D supplementation fails to reduce multiple sclerosis activity after clinically isolated syndrome: Study
Australia: Vitamin D supplementation is safe and well-tolerated but failed to alter the multiple sclerosis (MS) disease activity and did not lower the risk of developing clinically definite MS in patients with high-risk clinically isolated syndrome, a recent study has shown.
In the double-blinded clinical trial published in Brain, the hazard ratios for conversion to clinically definite multiple sclerosis based on the vitamin D3 dose were 0.87 for 1000 IU, 1.37 for 5000 IU, and 1.28 for 10,000 IU compared with placebo.
Low serum 25-hydroxyvitamin D (25(OH)D) levels and low sunlight exposure are known risk factors for MS development. Therefore, Vitamin D supplementation is routinely recommended for patients with multiple sclerosis. However, no strong evidence exists supporting the role of vitamin D supplementation in reducing the progression rates or relapse rates among patients with MS.
To fill this knowledge gap, Bruce V Taylor, University of Tasmania, Hobart, Tasmania, Australia, and colleagues aimed to test the hypothesis that oral vitamin D3 supplementation in high-risk clinically isolated syndrome (abnormal MRI, at least three T2 brain and/or spinal cord lesions), delays time to conversion to definite multiple sclerosis, that all doses are safe and well tolerated, and that the therapeutic effect is dose-dependent.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.